Skip to main content
. Author manuscript; available in PMC: 2015 Nov 15.
Published in final edited form as: Clin Cancer Res. 2014 Sep 15;20(22):5808–5822. doi: 10.1158/1078-0432.CCR-14-0234

Figure 2. The methylation status of miR-148a is prognostic in GBM and Grade III gliomas.

Figure 2

A, Kaplan–Meier overall survival analysis of GBM patients in the validation cohort (n=224). Survival among miR-148a-Methylated (n=29, solid line) and miR-148a-Unmethylated (n=195, dotted line) patients is shown. B, Kaplan–Meier overall survival analysis of Grade III glioma patients in the validation cohort (n=42, solid line). Survival among miR-148a-Methylated (n=30) and miR-148a-Unmethylated (n=12, dotted line) patients is shown.